Nanobiotix S.A. ADR (NBTX)

$29.03 -2.57 (-8.15%)
Market Cap 1.41B
Revenue (ttm) -7.78M
Net Income (ttm) -73.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 30.20
Profit Margin 947.69%
Debt to Equity Ratio 0.00
Volume 43,200
Avg Vol 39,026
Day's Range N/A - N/A
Shares Out 48.40M
Stochastic %K 3%
Beta 0.63
Analysts Strong Sell
Price Target $26.00

Company Profile

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 40 26 04 70
Fax: 33 1 40 26 04 44
Address:
60 rue de Wattignies, Paris, France
PhishTourFunds
PhishTourFunds Mar. 13 at 2:22 PM
$NBTX Movin
0 · Reply
focafoca99
focafoca99 Mar. 12 at 10:26 PM
$NBTX current 6-K was mostly a capital-and-voting-rights style update
0 · Reply
Billianas
Billianas Mar. 12 at 1:11 PM
$NBTX take short profit, retest 42$ and short it back https://stocktwits.com/Billianas/message/647101644
0 · Reply
medguy
medguy Mar. 12 at 4:15 AM
Looking for bounce $HMY $FICO $BWLP $NBTX $CDRE
0 · Reply
Billianas
Billianas Mar. 10 at 1:56 PM
$NBTX overpriced, wait for 15$ level for entry. $XBI $IBB
0 · Reply
marvelousTrades
marvelousTrades Mar. 9 at 6:11 PM
$NBTX moving to $KRRO thanks! for the run..
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 9 at 5:07 PM
$NBTX
0 · Reply
StocketShip
StocketShip Mar. 9 at 3:11 PM
$NBTX I don't understand this incredible run.....happy, but why so high?
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 5 at 12:01 AM
$NBTX It’s how things work 👌🏼
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 1 at 6:28 AM
$NBTX NanoFlakes, bruh
0 · Reply
Latest News on NBTX
Voting Rights and Shares Capital of the Company

Thu, 12 Mar 2026 16:15:00 -0400 - 9 days ago

Voting Rights and Shares Capital of the Company

NANOBIOTIX to Participate in Investor Conferences in March

Wed, 25 Feb 2026 16:15:00 -0500 - 24 days ago

NANOBIOTIX to Participate in Investor Conferences in March

Voting Rights and Shares Capital of the Company

Tue, 17 Feb 2026 16:15:00 -0500 - 4 weeks ago

Voting Rights and Shares Capital of the Company

Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News

2026-02-06T15:30:21.000Z - 6 weeks ago

Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News

Voting Rights and Shares Capital of the Company

Tue, 13 Jan 2026 16:15:00 -0500 - 2 months ago

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company

Wed, 17 Dec 2025 16:15:00 -0500 - 3 months ago

Voting Rights and Shares Capital of the Company

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

Mon, 15 Dec 2025 02:30:00 -0500 - 3 months ago

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

Mon, 24 Nov 2025 16:15:00 -0500 - 4 months ago

Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

Mon, 24 Nov 2025 10:29:00 -0500 - 4 months ago

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

Thu, 13 Nov 2025 16:15:00 -0500 - 4 months ago

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

Mon, 03 Nov 2025 16:15:00 -0500 - 4 months ago

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty

2025-10-31T10:53:35.000Z - 5 months ago

Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

Fri, 31 Oct 2025 03:00:00 -0400 - 5 months ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results

2025-10-02T17:00:59.000Z - 6 months ago

Nanobiotix (NBTX) Sees Stock Rise on Promising Cancer Drug Trial Results

Top 2 Health Care Stocks That May Keep You Up At Night This Month

Thu, 02 Oct 2025 09:06:22 -0400 - 6 months ago

Top 2 Health Care Stocks That May Keep You Up At Night This Month

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

Wed, 01 Oct 2025 16:15:00 -0400 - 6 months ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

Tue, 30 Sep 2025 16:15:00 -0400 - 6 months ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer

2025-09-30T17:43:20.000Z - 6 months ago

Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Mon, 29 Sep 2025 18:30:00 -0400 - 6 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Thu, 18 Sep 2025 15:46:34 -0400 - 6 months ago

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

2025-09-18T19:46:34.000Z - 6 months ago

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday

2025-09-18T14:19:12.000Z - 6 months ago

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday

Nanobiotix (NBTX) Surges After Promising Phase 1 Results

2025-09-18T10:00:41.000Z - 6 months ago

Nanobiotix (NBTX) Surges After Promising Phase 1 Results

Nanobiotix (NBTX) Surges on Promising Phase 1 Data

2025-09-18T09:55:39.000Z - 6 months ago

Nanobiotix (NBTX) Surges on Promising Phase 1 Data

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Wed, 17 Sep 2025 16:15:00 -0400 - 6 months ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Tue, 02 Sep 2025 16:15:00 -0400 - 7 months ago

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

Mon, 07 Jul 2025 16:15:00 -0400 - 9 months ago

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

Wed, 28 May 2025 02:00:00 -0400 - 10 months ago

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

Wed, 21 May 2025 16:15:00 -0400 - 10 months ago

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Mon, 12 May 2025 02:00:00 -0400 - 11 months ago

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in ...

2025-05-05T07:15:39.000Z - 11 months ago

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in ...

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Mon, 05 May 2025 02:00:00 -0400 - 11 months ago

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Wed, 30 Apr 2025 02:00:00 -0400 - 11 months ago

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Wed, 02 Apr 2025 16:15:00 -0400 - 1 year ago

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Mon, 31 Mar 2025 02:00:00 -0400 - 1 year ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

Thu, 27 Mar 2025 16:15:00 -0400 - 1 year ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Thu, 20 Mar 2025 16:15:00 -0400 - 1 year ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden

2025-03-18T12:54:25.000Z - 1 year ago

Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Mon, 17 Mar 2025 16:15:00 -0400 - 1 year ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Baillie Gifford's Strategic Acquisition of Nanobiotix SA Shares

2025-02-12T16:29:50.000Z - 1 year ago

Baillie Gifford's Strategic Acquisition of Nanobiotix SA Shares

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Wed, 29 Jan 2025 16:15:00 -0500 - 1 year ago

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Tue, 21 Jan 2025 02:30:00 -0500 - 1 year ago

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Tue, 17 Dec 2024 16:15:00 -0500 - 1 year ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Dec 9, 2024, 4:15 PM EST - 1 year ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

NBTX

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Nov 12, 2024, 2:30 AM EST - 1 year ago

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

NBTX

NANOBIOTIX to Participate in Multiple Investor Conferences in November

Oct 31, 2024, 3:30 AM EDT - 1 year ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November

NBTX

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Sep 18, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

NBTX

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Sep 4, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

NBTX

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

NBTX

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Jun 12, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

NBTX

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

Jun 2, 2024, 10:00 AM EDT - 1 year ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

NBTX

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

May 28, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

NBTX

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

NBTX

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

May 22, 2024, 2:00 AM EDT - 1 year ago

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

NBTX

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

May 21, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

NBTX

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

May 15, 2024, 4:15 PM EDT - 2 years ago

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

NBTX

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

May 14, 2024, 4:15 PM EDT - 2 years ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

NBTX

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Apr 24, 2024, 4:40 PM EDT - 2 years ago

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

NBTX

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Apr 17, 2024, 4:15 PM EDT - 2 years ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

NBTX

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Apr 2, 2024, 4:15 PM EDT - 2 years ago

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

NBTX

Nanobiotix to Present at Upcoming Investor Conferences in March

Mar 6, 2024, 4:15 PM EST - 2 years ago

Nanobiotix to Present at Upcoming Investor Conferences in March

NBTX

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Jan 31, 2024, 4:15 PM EST - 2 years ago

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

NBTX

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Jan 29, 2024, 4:15 PM EST - 2 years ago

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

NBTX

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

NBTX

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Nov 9, 2023, 4:15 PM EST - 2 years ago

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

NBTX

NANOBIOTIX Announces Closing of Global Offering

Nov 7, 2023, 4:01 PM EST - 2 years ago

NANOBIOTIX Announces Closing of Global Offering

NBTX

PhishTourFunds
PhishTourFunds Mar. 13 at 2:22 PM
$NBTX Movin
0 · Reply
focafoca99
focafoca99 Mar. 12 at 10:26 PM
$NBTX current 6-K was mostly a capital-and-voting-rights style update
0 · Reply
Billianas
Billianas Mar. 12 at 1:11 PM
$NBTX take short profit, retest 42$ and short it back https://stocktwits.com/Billianas/message/647101644
0 · Reply
medguy
medguy Mar. 12 at 4:15 AM
Looking for bounce $HMY $FICO $BWLP $NBTX $CDRE
0 · Reply
Billianas
Billianas Mar. 10 at 1:56 PM
$NBTX overpriced, wait for 15$ level for entry. $XBI $IBB
0 · Reply
marvelousTrades
marvelousTrades Mar. 9 at 6:11 PM
$NBTX moving to $KRRO thanks! for the run..
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 9 at 5:07 PM
$NBTX
0 · Reply
StocketShip
StocketShip Mar. 9 at 3:11 PM
$NBTX I don't understand this incredible run.....happy, but why so high?
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 5 at 12:01 AM
$NBTX It’s how things work 👌🏼
0 · Reply
PhishTourFunds
PhishTourFunds Mar. 1 at 6:28 AM
$NBTX NanoFlakes, bruh
0 · Reply
marvelousTrades
marvelousTrades Feb. 27 at 7:29 PM
$NBTX -> $KRRO
0 · Reply
PhishTourFunds
PhishTourFunds Feb. 27 at 4:20 PM
$NBTX Back to $30 and now ready to move up
0 · Reply
kshonstocks
kshonstocks Feb. 27 at 3:52 PM
keep eye on this $NBTX, acts well
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 6:47 PM
$NBTX RSI: 66.71, MACD: 1.2134 Vol: 2.15, MA20: 22.78, MA50: 22.17 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OnlyGB
OnlyGB Feb. 12 at 12:34 PM
$AZN $DRTS $NBTX this post from ‘25 turned out to be GOLD. $DRTS is up over 40%+ since it posted!
1 · Reply
PhishTourFunds
PhishTourFunds Feb. 10 at 10:52 PM
$NBTX
0 · Reply
Zaksab
Zaksab Feb. 10 at 3:34 PM
$NBTX accumulation
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 12:31 AM
$NBTX Current Stock Price: $23.86
0 · Reply
topstockalerts
topstockalerts Feb. 9 at 2:52 PM
$NBTX Bulls stepping on the gas 🙌. Price is accelerating higher. Momentum is clearly in control.
0 · Reply
erevnon
erevnon Feb. 6 at 3:00 PM
Guggenheim maintains Nanobiotix $NBTX at Buy and raises the price target from $8 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 27 at 9:22 AM
$NBTX Trading at $21.52, it's been a bit calmer lately with average volume at 36,172, compared to recent days.
0 · Reply